MECHELEN, BELGIUM--(Marketwire - March 20, 2013) -
Live presentation at 8 AM ET in New York City
Webcast at 1 PM CET/12 PM GMT, www.glpg.com, 2290 1608
Mechelen, Belgium; 20 March 2013 - Galapagos NV (Euronext: GLPG) will
host its annual R&D update in New York City on Wednesday, 27 March.
Formal proceedings will begin at 8:00 am Eastern Time/1:00 pm Central
European Time and end at approximately 10:00 am ET/3:00 pm CET. The
event will include presentations from Onno van de Stolpe, CEO, and Dr Piet
Wigerinck, CSO, who will discuss the progress in the portfolio of novel
mode-of-action medicines, and include the plans for the upcoming
Phase 2b trial of its selective JAK1 inhibitor GLPG0634.
The presentation will be webcast live and archived on Galapagos' website
for one year. To access the live webcast, go to www.glpg.com or click
here, call number 2290-1608. To attend this meeting in person,
please contact Elizabeth Goodwin at email@example.com.
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-
action, with a large pipeline of four clinical, six pre-clinical, and
30 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications. GLPG0634 is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other
inflammatory diseases, about to enter Phase 2b studies. AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will
be responsible for further development and commercialization after
Phase 2b. Galapagos has another selective JAK1 inhibitor in Phase 2
in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974
is the first inhibitor of GPR43 to be evaluated clinically for the
treatment of IBD; this program will start a Proof of Concept Phase 2 study
in Q2 2013. The Galapagos Group, including fee-for-service companies
BioFocus, Argenta and Fidelta, has over 800 employees and operates
facilities in five countries, with global headquarters in Mechelen,
Belgium. Further information at: www.glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could," "stands to," and "continues," as well as similar expressions. Such
forward- looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events, conditions
or circumstances on which any such statement is based, unless required by
law or regulation.
Galapagos to host annual R&D update on 27 March:
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE